CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.

Badar, Talha, Shah, Nirav N. · 2020 · Current Treatment Options in Oncology

Abstract

Opinion statement Chimeric receptor antigen (CAR) T cells are an innovative cellular immunotherapeutic approach that involves genetic modification of T cells to express CAR targeting tumor antigen. Prior to the development of CAR-T, the only potential cure for patients with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) was allogeneic hematopoietic stem cell transplantation (HSCT). Several CAR-T cell products have been studied in prospective clinical trials which ultimately have resulted in the approval of one anti-CD19 CAR-T cell product in pediatric RR ALL: tisagenlecleucel (CD3ζ and 41BB). While some patients achieve durable responses with CAR-T, lack of response and relapse remains clinical challenges. Reasons for sub-optimal response include lack of CAR-T cell persistence and target antigen down-regulation. Future CARs are under development to improve long-term persistence and to be able to overcome resistance mechanisms associated with the disease and the hostile tumor microenvironment. With evolving understanding about CARs and new constructs under investigation, there is optimism that future products will improve the safety and efficacy from the current standard of care.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11864-020-0706-6

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Schultz LM, Davis KL, Baggott C, Chaudry C, Marcy AC, Mavroukakis S, et al. Phase 1 Study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B Cell Acute lymphoblastic leukemia (ALL). 2018;132(Suppl 1):898-. · DOI

Cited by

See all 27

Metadata

Authors
Badar, T., & Shah, N. N.
Affiliations
Medical College of Wisconsin (US)
Venue
Current Treatment Options in Oncology
Published
2020-02
Volume
21
Issue
2
Pages
16-16
ISSN
  • 1527-2729 (ISSN-L)
  • 1534-6277
OpenAlex
W3005227279
Cited by
27
References
39
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 7
FWCI
0.51
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Treatment Options in Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor T cells, CAR T-cell therapy, acute lymphoblastic leukemia, relapsed/refractory leukemia, tisagenlecleucel, anti-CD19 CAR, CAR T cell persistence, tumor microenvironment, pediatric leukemia, allogeneic hematopoietic stem cell transplantation
MeSH terms
Receptors, Chimeric Antigen, Antigens, Neoplasm, Clinical Trials as Topic, Combined Modality Therapy, Cost-Benefit Analysis, Genetic Engineering, Humans, Lymphocyte Depletion, Prognosis, Receptors, Antigen, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Antigens, CD19, Disease Management, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1007/s11864-020-0706-6
The paper
Badar, T., & Shah, N. N. (2020). Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-020-0706-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.